Caracterización y prevalencia del compromiso ocular en pacientes con enfermedad autoinmune y autoinflamatoria en un centro de referencia reumatológica en Colombia entre los años 2000 a 2015

dc.contributorde-la-Torre, Alejandra
dc.contributorMantilla Hernández, Rubén Darío
dc.creatorVargas Villanueva, Andrés
dc.creatorSarmiento Forero, Diana Marcela
dc.date.accessioned2016-10-21T15:50:03Z
dc.date.available2016-10-21T15:50:03Z
dc.date.created2016-10-21T15:50:03Z
dc.date.issued2016
dc.identifierhttp://repository.urosario.edu.co/handle/10336/12479
dc.identifierhttps://doi.org/10.48713/10336_12479
dc.description.abstractObjectives: To estimate the prevalence of various ocular diseases occuring in the context of an autoimmune disease in patients from a rheumatology clinic referral center in Colombia, according to clinical features and socio-demographic factors from 2000 to 2015. Methods: We conducted an observational, descriptive prevalence study. Randomized stratified sampling with proportional assignment was carried out using Epidat 3.4. Data analysis was fulfilled through SPSS v22.0. Categorical variables were subjected to univariate analysis. Measures of central tendency were performed for cuantitative variables. Results: Ocular involvement was present in 634 patients (38,65%). Excluding patients with Sjögren´s syndrome (SS) and dry eye, which account for 100% (by definition, dry eye is present in all patients with SS), ocular involvement was present in 222 patients (13,53%). 83,3% subjects were women. Rheumatoid arthritis (RA) posed the greatest eye disease prevalence (62,2%), sarcoidosis the lesser (10%). Keratoconjunctivitis sicca (KCS) was the most common ophthalmic manifestation (63,5%) in all autoimmune diseases except the spondyloarthropaties. Out of 414 patients with SS and KCS, additional eye disease was present on 8 individuals, the most common being uveitis (10,6%). The highest prevalence of corticosteroid drug usage (88,8%) was present in patients with cataract (4.1% of the total population). 28 of 222 (12,6%) patients had uveitis. 16 (7,2%) of the total patients (and 18,75% of the total patients with Systemic lupus erythematosus –SLE- ) had ocular toxicity due to antimalarial drugs. Antinuclear antibodies were present in the whole vascular retinal disease group. The highest anti-DNA antibody serum positivity was present in patients with episcleritis; accordingly, SLE rendered the highest episcleritis prevalence (12,5%). 22% of anti-RNP positive patients presented scleritis. 32,1% of uveitis patients were HLA-B27 positive. Eye manifestations preceded systemic involvement in 11,1 to 33,3% of patients. Conclusions: Eye disease is present with relative frequency in Colombian patients with autoimmune disease (38,65%), RA being the condition with the highest prevalence (62,2%) and KCS being the most prevalent ocular manifestation (63,5%). 12,6% of patients had uveitis. On occasion, eye disease can precede systemic compromise. Eye examination should be included as part of these patient population assessment because it is a frequent co-morbidity. In addition, rheumatic drug ocular adverse effects should be monitored during the course of treatment.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherFacultad de medicina
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceSantos-Bacchiega AB, Gomes Ochtrop ML, De Souza AWS. Chapter 36: Systemic Vasculitis. In: Autoimmunity: From Bench to Bedside: 1st ed. Bogotá: Universidad del Rosario; 2013. p. 621–42. 2. Generali E, Cantarini L, Selmi C. Ocular Involvement in Systemic Autoimmune Diseases. Clin Rev Allergy Immunol [Internet]. 2015;(October):263–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26494481 3. McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. Ocul Surf [Internet]. 2015;14(2):144–67. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1542012415002049 4. Collier SA, Gronostaj MP, MacGurn AK, Cope JR, Awsumb KL, Yoder JS, et al. Estimated Burden of Keratitis — United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(45):1027–30. 5. Adán-Civera AM, Benítez-Del-Castillo JM, Blanco-Alonso R. Burden and Direct Costs of Non Infectious Uveitis in Spain ଝ. 2016;12(4):196–200. 6. Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg R a, Duh MS. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect [Internet]. 2013;3(1):64. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3830557&tool=pmcentrez&rendertype=abstract 7. Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol. 2016;331–9. 8. Hessen M, Akpek EK. Dry eye: An inflammatory ocular disease. J Ophthalmic Vis Res. 2014;9(2):240–50. 9. Foulks GN, Lemp MA, Jester J V, Sutphin J, Murube J, Novack GD. The Epidemiology of Dry Eye Disease. Report of the International Dry Eye Workshop (DEWS). The Ocular Surface. New York; 2007. 10. Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7(1):57. 11. Lee RW, Nicholson LB, Sen HN, Chan CC, Wei L, Nussenblatt RB, et al. Autoimmune and autoinflammatory mechanisms in uveitis. Semin Immunopathol. 2014;581–94. 12. Ucar-Comlekoglu D, Fox A, Sen HN. Gender differences in Behcet’s disease associated uveitis. J Ophthalmol. Hindawi Publishing Corporation; 2014;2014. 13. Dartt DA. Introduction. In: Dartt DA, D’amore P, Dana R, Niederkorn JY, editors. Immunology, inflammation and diseases of the eye. 1st ed. Oxford: Elsevier Inc.; 2011. 14. Li Z, Liu B, Maminishkis A, Mahesh SP, Yeh S, Lew J, et al. Gene Expression Profiling in Autoimmune Noninfectious Uveitis Disease. J Immunol. 2008;181(7):5147–57. 15. Gold R, Hartung H-P, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci. Elsevier; 1997 Sep;20(9):399–404. 16. Bauer J, Bradl M, Hickley WF, Forss-Petter S, Breitschopf H, Linington C, et al. T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am J Pathol. 1998;153(3):715–24. 17. Forrester J V., Xu H, Kuffov?? L, Dick AD, McMenamin PG. Dendritic cell physiology and function in the eye. Immunol Rev. 2010;234(1):282–304. 18. Copland DA, Calder CJ, Raveney BJE, Nicholson LB, Phillips J, Cherwinski H, et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol. 2007 Aug;171(2):580–8. 19. Horie S, Robbie SJ, Liu J, Wu W-K, Ali RR, Bainbridge JW, et al. CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization. Sci Rep. 2013;3:3072. 20. Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2005;50(4):351–63. 21. Cocho L, Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Sainz-de-la-Maza M, Foster CS. Scleritis in patients with granulomatosis with polyangiitis (Wegener). Br J Ophthalmol. 2015;1–4. 22. Jabs D a, Mudun a, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469–76. 23. Fong LP1, Sainz de la Maza M, Rice BA, Kupferman AE FC. Immunopathology of scleritis. Ophthalmology. 1991;98(4):472–9. 24. Yagci A, Gurdal C. The role and treatment of inflammation in dry eye disease. Int Ophthalmol. 2014;34(6):1291–301. 25. Cejková J, Ardan T, Simonová Z, Cejka C, Malec J, Jirsová K, et al. Nitric oxide synthase induction and cytotoxic nitrogen-related oxidant formation in conjunctival epithelium of dry eye (Sjögren’s syndrome). Nitric Oxide. 2007 Aug;17(1):10–7. 26. Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li D-Q. Stress-activated Protein Kinase Signaling Pathways in Dry Eye and Ocular Surface Disease. Ocul Surf. 2005 Oct;3(4):S-154-S-157. 27. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Investig Ophthalmol Vis Sci. 2004;45(12):4293–301. 28. Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK. Systemic lupus erythematosus: An update for ophthalmologists. Surv Ophthalmol [Internet]. Elsevier Inc; 2016;61(1):65–82. Available from: http://dx.doi.org/10.1016/j.survophthal.2015.06.003 29. Palejwala N V., Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: A review of the literature. Autoimmune Dis. 2012;1(1). 30. Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007 Dec;46(12):1757–62. 31. Ausayakhun S, Louthrenoo W, Aupapong S. Ocular diseases in patients with rheumatic diseases. J Med Assoc Thai. 2002;85(8):855–62. 32. Fujita M, Igarashi T, Kurai T, Sakane M, Yoshino S, Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. 2005;140(5):808–13. 33. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Investig Ophthalmol Vis Sci. 2001;42(10):2283–92. 34. Grange LK, Kouchouk A, Dalal MD, Vitale S, Nussenblatt RB, Chan C-C, et al. Neoplastic masquerade syndromes in patients with uveitis. Am J Ophthalmol. Elsevier; 2014 Mar;157(3):526–31. 35. Rothova a, Buitenhuis HJ, Meenken C, Brinkman CJ, Linssen a, Alberts C, et al. Uveitis and systemic disease. Br J Ophthalmol. 1992;76(3):137–41. 36. Copland DA, Liu J, Schewitz-Bowers LP, Brinkmann V, Anderson K, Nicholson LB, et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. Am J Pathol. 2012;180(2):672–81. 37. Turner DL, Bickham KL, Thome JJ, Kim CY, D’Ovidio F, Wherry EJ, et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. Society for Mucosal Immunology; 2014 May;7(3):501–10. 38. Peters A, Pitcher L, Sullivan J. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. 2011;35(6):986–96. 39. Generali E, Ceribelli A, Massarotti M, Cantarini L, Selmi C. Seronegative reactive spondyloarthritis and the skin. Clin Dermatol. Elsevier Inc.; 2015;33(5):531–7. 40. Foeldvari I. Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment. Clin Rev Allergy Immunol. 2014;49(3):271–7. 41. de-la-Torre A, L??pez-Castillo CA, Rueda JC, Mantilla RD, G??mez-Mar??n JE, Anaya JM. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin Exp Ophthalmol. 2009;37(5):458–66. 42. Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014;13(4–5):591–4. 43. McCluskey P, Powell RJ, Powell PRJ, Powell RJ. The eye in systemic inflammatory diseases. Lancet [Internet]. 2004;364(9451):2125–33. Available from: http://www.sciencedirect.com/science/article/B6T1B-4F0G25R-11/2/aea51fb6d246044cf83c27268c5b49a5\nhttp://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T1B-4F0G25R-11-1&_cdi=4886&_user=1676895&_pii=S0140673604175545&_origin=gateway&_coverDate=12/17/20 44. Barbosa-Cobos RE, Recillas-Gispert C, Arellanes-García L. Manifestaciones oculares de las vasculitis primarias sistémicas. Reumatol Clin. 2011;7(SUPPL. 3):12–7. 45. Perez VL, Chavala SH, Ahmed M, Chu D, Zafirakis P, Baltatzis S, et al. Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol. 2004;49(4):399–418. 46. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999;43(5):379–96. 47. Garrity JA. Ocular manifestations of small-vessel vasculitis. Cleve Clin J Med. 2012;79(Suppl.3):31–3. 48. Tarabishy AB, Schulte M, Papaliodis GN, Hoffman GS. Wegener’s granulomatosis: Clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv Ophthalmol [Internet]. Elsevier Inc; 2010;55(5):429–44. Available from: http://dx.doi.org/10.1016/j.survophthal.2009.12.003 49. Toh T, Cooper RL, Parker A, Vote BJ. Wegener’s granulomatosis presenting with painless bulbar-conjunctival ulcer and central retinal artery occlusion. Clin Exp Ophthalmol. 2006;34(1):51–3. 50. Pakrou N, Selva D, Leibovitch I. Wegener’s Granulomatosis: Ophthalmic Manifestations and Management. Semin Arthritis Rheum. 2006;35(5):284–92. 51. Cuende E, Ruiz Mena A, Andonegui J, Minguela I, Vesga J. Rheumatology 2001;40:1066–1068 Ocular involvement in Wegener’s granulomatosis responding to intravenous cyclophosphamide S. Rheumatology (Oxford). 2001;40:1066–8. 52. Tullo AB, Durrington P, Graham E, Holt LP, Easty DL, Bonshek R, et al. Florid xanthelasmata (yellow lids) in orbital Wegener’s granulomatosis. Br J Ophthalmol. 1995;79:453–6. 53. Talar-Williams C, Sneller MC, Langford CA, Smith JA, Cox TA, Robinson MR. Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener’s granulomatosis. Br J Ophthalmol [Internet]. 2005;89(4):493–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1772590&tool=pmcentrez&rendertype=abstract 54. Ostri C, Heegaard S, Prause JU. Sclerosing Wegener’s granulomatosis in the orbit. Acta Ophthalmol. 2008;86(8):917–20. 55. Khanna D, Shrivastava A. Suppurative dacroadenitis causing ocular sicca syndrome in classic Wegener’s granulomatosis. Indian J Ophthalmol [Internet]. 2011;59(2):151–3. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3116546&tool=pmcentrez&rendertype=abstract 56. Chua J, Lim L. Systemic Wegener’s granulomatosis with severe orbito-ocular involvement. 2008;49(10):259–62. 57. Chan AY. Unusual eye signs in Wegener ’ s granulomatosis. Hong Kong Med J. 2007;13(3):241–2. 58. Ameli F, Phang KS, Masir N. Churg-Strauss syndrome presenting with conjunctival and eyelid masses: A case report. Med J Malaysia. 2011;66(5):517–9. 59. Acheson JF, Cockerell OC, Bentley CR, Sanders MD. Churg-Strauss vasculitis presenting with severe visual loss due to bilateral sequential optic neuropathy. Br J Ophthalmol [Internet]. 1993;77(2):118–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=504444&tool=pmcentrez&rendertype=abstract 60. Takanashi T, Uchida S, Arita M, Okada M, Kashii S. Orbital inflammatory pseudotumor and ischemic vasculitis in Churg-Strauss syndrome - Report of two cases and review of the literature. Ophthalmology [Internet]. 2001;108(6):1129–33. Available from: WOS:000169027100044 61. Sutcliffe N, Morris V, Gomperts B, Brazier DJ, Isenberg D a, Cambridge G. Relationship between the development of blindness in Churg-Strauss syndrome and anti-myeloperoxidase antibodies. Br J Rheumatol. 1997;36:273–5. 62. Rahman W, Rahman FZ. Giant cell (temporal) arteritis: An overview and update. Surv Ophthalmol. 2005;50(5):415–28. 63. De-la-Torre A, Lopez-Castillo CA, Rueda JC, Mantilla RD, Gomez-Marin JE, Anaya JM. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin Exp Ophthalmol. 2009;37(5):458–66. 64. Paovic J, Paovic P, Sredovic V. Behcet’s disease: Systemic and ocular manifestations. Biomed Res Int. 2013;2013. 65. Kacmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, et al. Ocular Inflammation in Behcet Disease: Incidence of Ocular Complications and of Loss of Visual Acuity. Am J Ophthalmol [Internet]. Elsevier Inc.; 2008;146(6):828–36. Available from: http://dx.doi.org/10.1016/j.ajo.2008.06.019 66. Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behcet’s disease in Turkey. Ophthalmology [Internet]. 1997;104(4):701–5. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9111266 67. Ortona E, M P, A M, C V. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita. 2016;52(2):205–12. 68. Reddy S, Gupta S, Deodhar S, Jain I. Ocular manifestations of rheumatoid arthritis. Indian J Ophthalmol. 1977;25(3):20–6. 69. Carbone J, Sarmiento E, Micheloud D, Rodríguez-Mahou M, Rodríguez-Molina J, Cobo R, et al. Systemic autoimmune disease in patients with uveitis. Arch Soc Esp Oftalmol. 2006;81(4):193–8. 70. Fujita M, Igarashi T, Kurai T, Sakane M, Yoshino S, Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. 2005;140(5):808–13. 71. Mohsenin A, Huang JJ. Ocular manifestations of systemic inflammatory diseases. Conn Med. 2012;76(9):533–44. 72. Stephen C Foster AB. Ocular Manifestations of Systemic Lupus Erythematosus. J Clin Cell Immunol [Internet]. 2014;5(1):1–9. Available from: http://www.omicsonline.org/clinical-cellular-immunology-abstract.php?abstract_id=24429 73. Sainz De La Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology [Internet]. Elsevier Inc.; 2012;119(1):43–50. Available from: http://dx.doi.org/10.1016/j.ophtha.2011.07.013 74. Heiligenhaus A, Wefelmeyer D, Wefelmeyer E, Rösel M, Schrenk M. The eye as a common site for the early clinical manifestations of sarcoidosis. Ophthalmic Res. 2011;46:9–12. 75. Lima FBF de, Abalem MF, Ruiz DG, Gomes B de AF, Azevedo MNL de, Moraes H V, et al. Prevalence of eye disease in Brazilian patients with psoriatic arthritis. Clin (São Paulo, Brazil) [Internet]. 2012;67(3):249–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22473406\nhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3297034 76. Cantini F, Nannini C, Cassar?? E, Kaloudi O, Niccoli L. Uveitis in spondyloarthritis: An overview. J Rheumatol. 2015;93:27–9.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectEnfermedad autoinmune
dc.subjectCompromiso ocular
dc.subjectPrevalencia
dc.subjectUveítis
dc.subjectQueraconjuntivitis
dc.subjectSicca
dc.titleCaracterización y prevalencia del compromiso ocular en pacientes con enfermedad autoinmune y autoinflamatoria en un centro de referencia reumatológica en Colombia entre los años 2000 a 2015
dc.typebachelorThesis


Este ítem pertenece a la siguiente institución